Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
TINDAMAX (tinidazole) is an oral nitroimidazole antimicrobial approved in 2004 for parasitic and protozoal infections. It functions as a broad-spectrum antimicrobial agent effective against anaerobic bacteria and select protozoans. The drug is administered orally in tablet form for systemic infections.
Product approaching loss of exclusivity with moderate competitive pressure (30/100); expect resource reallocation from brand team toward line extensions or next-generation assets.
Nitroimidazole Antimicrobial
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
"Sexual Health Assessment of TinidaZole Against M. Genitalium (SHAZAM)"
Tinidazole for Recurrent Bacterial Vaginosis: A Pilot Study
NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole)
Treatment of Bacterial Vaginosis With Oral Tinidazole
Treatment of Bacterial Vaginosis (BV) With Tinidazole
Worked on TINDAMAX at Mission Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
TINDAMAX presents limited career growth opportunity given its approaching LOE status and lack of linked job postings. Working on this product suits roles focused on defensive commercial strategy, managed care relationships, and mature market management rather than innovation or launch activities.